Results 141 to 150 of about 691,224 (357)

Takotsubo cardiomyopathy during armed conflict: A case series

open access: yes
ESC Heart Failure, Volume 12, Issue 2, Page 1494-1498, April 2025.
Sharon Bruoha   +13 more
wiley   +1 more source

Cardiometabolic outcomes with dapagliflozin after myocardial infarction by baseline ejection fraction: DAPA‐MI

open access: yesESC Heart Failure, EarlyView.
We investigated cardiometabolic outcomes in patients treated with dapagliflozin 10 mg once daily or placebo after acute myocardial infarction according to LVEF at randomisation in the registry‐based, randomised DAPA‐MI trial. Regardless of baseline LVEF, dapagliflozin resulted in significant cardiometabolic benefits versus placebo, suggesting that ...
David Erlinge   +19 more
wiley   +1 more source

Ischemia/Reperfusion Injury following Acute Myocardial Infarction: A Critical Issue for Clinicians and Forensic Pathologists

open access: yesMediators of Inflammation, 2017
Acute myocardial infarction (AMI) is a leading cause of morbidity and mortality. Reperfusion strategies are the current standard therapy for AMI. However, they may result in paradoxical cardiomyocyte dysfunction, known as ischemic reperfusion injury (IRI)
Margherita Neri   +4 more
doaj   +1 more source

Soluble urokinase plasminogen activator receptor and outcomes in HFpEF: A TOPCAT ancillary study

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Inflammation is postulated to be a key pathogenic mechanism in heart failure with preserved ejection fraction (HFpEF). Soluble urokinase plasminogen activator receptor (suPAR), a regulator of innate immune activity, is associated with incident heart failure; however, its role in HFpEF remains unclear.
Christina G. Hutten   +9 more
wiley   +1 more source

Adenosine triphosphate–dependent potassium channel modulation and cardioplegia-induced protection of human atrial muscle in an in vitro model of myocardial stunning [PDF]

open access: bronze, 2000
Francesco Monti   +9 more
openalex   +1 more source

Prognostic impact of SCAI shock severity classes in AMI‐related cardiogenic shock: A sub‐study of the ECLS‐SHOCK Trial

open access: yesESC Heart Failure, EarlyView.
Patients with AMI‐CS (lactate >3 mmol/L) enrolled in the multicentre, randomized ECLS‐SHOCK trial were included. From a total of 417 patients, 51.6% (n = 215), 13.4% (n = 56) and 35.0% (n = 146) presented in SCAI Stages C, D and E, respectively. SCAI stages were associated with the risk of 30 day all‐cause mortality, with rates of renal replacement ...
Janine Pöss   +13 more
wiley   +1 more source

Integrated role of cardiac magnetic resonance and genetics in predicting left ventricular reverse remodelling in dilated and non‐dilated cardiomyopathy

open access: yesEuropean Journal of Heart Failure, EarlyView.
An integrated approach including late gadolinium enhancement data and genetics to predict left ventricular reverse remodelling in patients with dilated and non‐dilated left ventricular cardiomyopathy. DSP, desmoplakin; FLNC, filamin C; LMNA, lamin A/C; LVRR, left ventricular reverse remodelling; LGE, late gadolinium enhancement; MVA, major ventricular ...
Martina Setti   +21 more
wiley   +1 more source

Takotsubo Syndrome in the Dialysis Patient - Challenging Diagnosis in a Unique Population. [PDF]

open access: yes, 2019
Banerjee   +9 more
core   +1 more source

Apical ballooning syndrome, case series [PDF]

open access: yes, 2008
Neðst á síðunni er hægt að nálgast greinina í heild sinni með því að smella á hlekkinn View/OpenApical ballooning syndrome is a cardiac syndrome typically characterized by transient focal dyskinesia or akinesia of the mid and apical regions of the left ...
Guðný Stella Guðnadóttir   +6 more
core  

Neurohumoral features of myocardial stunning due to sudden emotional stress.

open access: yesNew England Journal of Medicine, 2005
I. Wittstein   +9 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy